Product sales from acquired Horizon products contributed $4.2 billion in 2024, compared to $954 million in 2023. This indicates a successful integration and revenue generation from the acquired portfolio.

Amgen reported five Phase 3 data readouts for BLINCYTO, UPLIZNA, rocatinlimab, and TEZSPIRE, indicating progress in clinical development. This demonstrates a commitment to innovation and potential for future product launches.

BeiGene began selling XGEVA, BLINCYTO and KYPROLIS in China, with Amgen sharing profits and losses during initial commercialization periods. This collaboration expands Amgen's reach in a key market and diversifies its revenue streams.

Amgen completed the acquisition of Horizon on October 6, 2023, and integrated its operations into the company. This demonstrates management's ability to execute complex acquisitions and integrate new businesses.

Amgen is consolidating commercial production of select acquired Horizon products into its existing manufacturing network. This indicates management's focus on operational efficiency and cost optimization.

Amgen is under examination by the IRS and other tax authorities, with potential for significant adjustments to tax liabilities. This indicates a complex tax environment and potential challenges in managing tax obligations.

The 10-K explicitly states that Amgen faces increasing competition from biosimilars and generics, which could impact pricing and market share. Patents for key products like Prolia and XGEVA expire in February 2025, increasing the risk of sales erosion.

The 10-K highlights the risk of government and third-party policies impacting coverage and reimbursement, including the Inflation Reduction Act (IRA). This could negatively affect Amgen's profitability and access to its products.

The 10-K states that manufacturing difficulties, disruptions or delays could limit the supply of Amgen's products. A substantial portion of commercial manufacturing activities are performed in Puerto Rico, making the company vulnerable to natural disasters and other disruptions.

The 10-K explicitly states that Amgen faces increasing competition from biosimilars and generics, which could impact pricing and market share. This is a major competitive threat to the company's established products.

The 10-K highlights Amgen's efforts to increase the value of its medicines through innovations, including expanding disease areas and finding new methods of delivery. This is a key strategy to differentiate its products in a competitive market.

Amgen has its own biosimilar products both in the United States and outside of U.S. markets that are competing against branded and biosimilar versions of competitors' products. This demonstrates Amgen's ability to compete in the biosimilar market.

The 10-K states that Amgen is expanding its manufacturing capacity and incorporating state-of-the-art technologies, allowing it to optimize its manufacturing network and mitigate risks. This demonstrates a focus on improving operational efficiency.

Amgen's new state-of-the-art biomanufacturing plants have been constructed at a lower cost and with greater speed as compared to traditional facilities. This indicates improved operational efficiency in manufacturing.

The 10-K states that Amgen monitors the financial condition and manufacturing quality and compliance of key suppliers. This demonstrates a focus on mitigating supply chain risks and ensuring operational continuity.

The 10-K states that Dr. David M. Reese became the Company's inaugural Executive Vice President and Chief Technology Officer in December 2023, responsible for accelerating the use of technology and artificial intelligence across the organization. This demonstrates a commitment to innovation and technology.

The 10-K states that Amgen focuses its R&D on novel human therapeutics for the treatment of serious illness. This demonstrates a commitment to innovation and developing new medicines.

The 10-K states that Amgen has reshaped its portfolio and has increasingly focused its efforts on human genetics when possible to enhance the likelihood of success. This demonstrates a commitment to innovation and using cutting-edge science.

The 10-K states that Amgen expects to continue to pay quarterly dividends and repurchase stock. This demonstrates a commitment to returning capital to stockholders.

The 10-K states that Amgen expects to continue allocating significant resources to its R&D activities. This demonstrates a commitment to innovation and developing new medicines.

The 10-K states that Amgen is reducing its debt leverage levels before returning to the capital or credit markets for new funds. This demonstrates a commitment to financial stability and reducing risk.

The 10-K states that Amgen has a long-standing ambition to be environmentally responsible and regularly sets targets to challenge itself to deliver further improvements. This demonstrates a commitment to sustainability.

The 10-K states that Amgen announced a new set of long-term environmental targets to achieve by 2027, including achieving carbon neutrality, reducing water consumption by 40% and reducing waste disposed by 75%. This demonstrates a commitment to sustainability and specific goals.

The 10-K states that Amgen's goal is to have a world class safety record through safety leadership, engaged staff, risk management practices and integrating safety throughout its business processes. This demonstrates a commitment to safety and employee well-being.

The 10-K states that Amgen is continuously monitoring the possible impacts from health-related events, geopolitical conflicts and natural disasters. This demonstrates a proactive approach to managing risks in the market environment.

The 10-K states that Amgen is working to mitigate effects on future study enrollment in its clinical trials. This demonstrates a proactive approach to managing risks in the market environment.

The 10-K states that Amgen remains focused on supporting active clinical sites in their providing care for patients and in our providing investigational drug supply. This demonstrates a commitment to patients and the market.